by Nick Delesandro | Sep 5, 2026 | Science
Key Takeaways A new paper in the Journal of Psychopharmacology proposes explicit criteria for calling a compound “psychedelic,” aiming to resolve long-standing definitional ambiguity in clinical research. The authors argue that receptor pharmacology alone...
by Nick Delesandro | Sep 5, 2026 | Research & Science
Key Takeaways NCT06506019 is a Phase 1 trial examining psilocybin’s neurobiological effects in treatment-resistant bipolar II depression, a population historically excluded from psychedelic research. The study uses fMRI imaging to measure brain connectivity...
by Nick Delesandro | Aug 31, 2026 | Research & Science
Key Takeaways A new qualitative study published in the American Journal of Hospice and Palliative Medicine surveyed oncology providers about their readiness to incorporate psychedelic-assisted therapy into cancer care. Clinicians expressed cautious optimism but...
by Nick Delesandro | Aug 31, 2026 | Science
Key Takeaways A randomized crossover trial published in the Journal of Psychopharmacology compared three botanical formulations: oral psilocybin, oral psilocin, and sublingual psilocin. Sublingual psilocin produced faster onset and reached peak plasma concentrations...
by Nick Delesandro | Aug 12, 2026 | Science
Key Takeaways A 2025 review in Trends in Pharmacological Sciences examines how biological sex influences serotonergic signaling and psychedelic response. Differences in 5-HT2A receptor density and hormonal modulation may partly explain variable outcomes in psilocybin...
